JP2022500473A5 - - Google Patents

Info

Publication number
JP2022500473A5
JP2022500473A5 JP2021515046A JP2021515046A JP2022500473A5 JP 2022500473 A5 JP2022500473 A5 JP 2022500473A5 JP 2021515046 A JP2021515046 A JP 2021515046A JP 2021515046 A JP2021515046 A JP 2021515046A JP 2022500473 A5 JP2022500473 A5 JP 2022500473A5
Authority
JP
Japan
Prior art keywords
independently
alkyl
haloalkyl
cycloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021515046A
Other languages
English (en)
Japanese (ja)
Other versions
JP7412424B2 (ja
JP2022500473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051272 external-priority patent/WO2020060914A1/en
Publication of JP2022500473A publication Critical patent/JP2022500473A/ja
Publication of JP2022500473A5 publication Critical patent/JP2022500473A5/ja
Application granted granted Critical
Publication of JP7412424B2 publication Critical patent/JP7412424B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515046A 2018-09-18 2019-09-16 Lpaアンタゴニストとしてのオキサビシクロ酸 Active JP7412424B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732588P 2018-09-18 2018-09-18
US62/732,588 2018-09-18
PCT/US2019/051272 WO2020060914A1 (en) 2018-09-18 2019-09-16 Oxabicyclo acids as lpa antagonists

Publications (3)

Publication Number Publication Date
JP2022500473A JP2022500473A (ja) 2022-01-04
JP2022500473A5 true JP2022500473A5 (cg-RX-API-DMAC7.html) 2023-11-08
JP7412424B2 JP7412424B2 (ja) 2024-01-12

Family

ID=68073221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515046A Active JP7412424B2 (ja) 2018-09-18 2019-09-16 Lpaアンタゴニストとしてのオキサビシクロ酸

Country Status (7)

Country Link
US (1) US12428430B2 (cg-RX-API-DMAC7.html)
EP (1) EP3853232B1 (cg-RX-API-DMAC7.html)
JP (1) JP7412424B2 (cg-RX-API-DMAC7.html)
KR (1) KR102788997B1 (cg-RX-API-DMAC7.html)
CN (1) CN113366000A (cg-RX-API-DMAC7.html)
ES (1) ES2941774T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020060914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102800284B1 (ko) * 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527917A (en) 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
MA37439B1 (fr) 2012-04-27 2017-02-28 Novartis Ag Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
HK1206339A1 (en) 2012-06-20 2016-01-08 霍夫曼-拉罗奇有限公司 N-aryltriazole compounds as lpar antagonists
SG11201407220YA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-alkyltriazole compounds as lpar antagonists
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
JP7369125B2 (ja) 2017-12-19 2023-10-25 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸
PE20210655A1 (es) 2017-12-19 2021-03-31 Bristol Myers Squibb Co Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
KR102725744B1 (ko) 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126087A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
KR102800284B1 (ko) 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산

Similar Documents

Publication Publication Date Title
JP2022500470A5 (cg-RX-API-DMAC7.html)
JP2022500469A5 (cg-RX-API-DMAC7.html)
JP2021508686A5 (cg-RX-API-DMAC7.html)
JP2021507895A5 (cg-RX-API-DMAC7.html)
JP2021507896A5 (cg-RX-API-DMAC7.html)
JP2021506878A5 (cg-RX-API-DMAC7.html)
HRP20211918T1 (hr) Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
JP2021507900A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP6824954B2 (ja) mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール
JP6824952B2 (ja) mIDH1阻害剤としての2−アリール−および2−アリールアルキル−ベンズイミダゾール
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP7683930B2 (ja) セミカルバジド感受性アミンオキシダーゼ阻害剤の調製及びその応用
AU2019362770B2 (en) Radioligands for imaging the LPA1 receptor
JP2023544476A5 (cg-RX-API-DMAC7.html)
JP6783756B2 (ja) mIDH1阻害剤としてのベンゾイミダゾール−2−アミン
JP6830909B2 (ja) mIDH1阻害剤としてのN−メンチルベンズイミダゾール
JP2021502358A5 (cg-RX-API-DMAC7.html)
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
CN101945862A (zh) 用于治疗自身免疫性病症和炎性病症的四氢环戊二烯并[b]吲哚-3-基羧酸衍生物
US20140227191A1 (en) L-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
US12252472B1 (en) Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
JP2020503332A5 (cg-RX-API-DMAC7.html)
JP2024517769A5 (cg-RX-API-DMAC7.html)
JP2025510512A5 (cg-RX-API-DMAC7.html)